GLP Medication Linked to Lower Mortality and Cardiovascular Risk in Serious Mental Illness.

People living with serious mental illness can face increase risks of physical health conditions, including cardiovascular disease, and premature death. A 2026 study published in JAMA Psychiatry examined whether glucagon-like peptide-1 (GLP-1) receptors, a group of medications increasingly used in the treatment of type 2 diabetes and obesity, may also be associated with improved cardiovascular outcomes and lower mortality among people with serious mental illness. The researchers found that starting a GLP-1 receptor agonist was associated with lower rates of death and several major cardiovascular events when compared with another commonly used class of diabetes medication, sodium glucose cotransporter-2 (SGLT2) inhibitors.

 

Why Us Cardiovascular Health So Important in Serious Mental Illness?

The study focused on the people with major depressive disorder, bipolar and schizophrenia, which the researchers grouped under the term serious mental illness (SMI). People with these conditions experience a substantially higher burden of cardiovascular disease. McIntyre and colleagues note that life expectancy among people with serious mental illness has been estimated to be 10 to 25 years shorter than in the general population, with cardiovascular disease contributing significantly to this difference. Several factors may contribute, including higher rates of cardiometabolic risk factors, metabolic effects associated with some psychiatric medication and disparities in access to preventative healthcare, screening and treatment.

What are GLP-1 Receptor Agonists?

GLP-1 receptor agonists are medications that influence pathways involved in blood glucose regulation, appetite and metabolism. They are used for conditions including type 2 diabetes and obesity. Examples examined in the study include semaglutide, tirzepatide, dulaglutide, liraglutide and several other medications.

Previous research has demonstrated the benefits of GLP-1 receptors for weight and glucose management, while some studies have also identified cardiovascular benefits. Research involving people with serious mental illness has additionally suggested that these medications may help manage metabolic changes associated with some antipsychotic medications.

What Did the Study Investigate?

Researchers conducted a large retrospective study using electronic health record data from the multinational TriNetX Analysis network. They compared adults who had started a GLP-1 receptor agonist with adults who had started an SGLT2 inhibitor. Prosperity score matching was used to make the groups more comparable across a range of demographic, medical and psychiatric factors. For the primary four-year analysis, more than 1.5 million matched participants were included. Of these, approximately 390,000 were people classified as having a serious mental illness.

The researchers examined

  • All cause mortality
  • Major adverse cardiovascular events
  • Heart attack
  • Stroke
  • Coronary revascularisation

 

What Did the Researchers Find?

Among people with serious mental illness, 4.91% of those that started a GLP-1 receptor agonist died during the four-year analysis period, compared with 6.45% of those who started an SGL T2 inhibitor. This represents a 24% lower relative risk of death and an absolute risk difference of 1.54 percentage points. Differences were also apparent relatively early. At one year, mortality was 1.46% among people with serious mental health illness who had started GLP-1 receptor agonists compared with 2.84% among those who had started an SGL T2 inhibitor.

When researchers specifically examined people with serious mental illness and type 2 diabetes, starting semaglutide was also associated with lower rates of several cardiovascular outcomes, including major adverse cardiovascular events, heart attack, stroke, heart failure and coronary artery bypass grafting.

 

Were The Findings Similar Across Different Health Conditions?

Exploratory analysis looked separately at major depressive disorder, bipolar disorder and schizophrenia in people who also had type 2 diabetes. The introduction of semaglutide was associated with lower mortality compared with those taking a SGL T2 inhibitor across all three diagnostic groups.

 

The researchers also found that results differed between individuals GLP-1 medication. Semaglutide and tirzepatide were associated with the clearest mortality reduction, while older GLP-1receptor agonists did not show a consistent survival advantage. This suggests that the finding should not necessarily be assumed to apply equally to every medication within the GLP-1 receptor agonist class.

 

What Do These Findings Mean?

The results add to growing evidence that physical and mental healthcare need to be considered together. For people with serious mental illness, cardiovascular and metabolic health can have a significant effect on long term health outcomes. Treatment that addresses cardiometabolic risk may therefore have relevance beyond changes in weight or blood glucose alone. However, the study’s findings do not demonstrate that GLP-1 receptor agonists directly cause the reduction in mortality or cardiovascular events.

 

What Are the Limitations?

This was an observational study using existing health records rather than a randomised clinical trial. The authors also noted limitations including possible differences in medication adherence, lifestyle factors and socioeconomic circumstances, as well as inequalities in access to GLP-1 medications. Tirzepatide also had a shorter follow up period that some of the other treatments, meaning its findings require particularly cautious interpretations. Prospective randomised trials will be important in determining whether GLP-1 receptor agonists themselves reduce mortality and cardiovascular events in people with serious mental illness.

 

Looking After Physical and Mental Health

Mental health and physical health are closely connected. For people receiving treatment for conditions such as depression, bipolar or schizophrenia, monitoring cardiovascular and metabolic health can be an important part of ongoing care. Medication decisions should take into account an individual’s psychiatric and physical health, other medication, potential side effects and overall treatment needs.

If you have any concerns about your mental health or the metabolic effects of psychiatric medication, speak with your treating psychiatrist, GP or other healthcare professional.

 

Source

McIntyre, R. S., Zhang-James, Y., & Kwan, A. T. (2026). Glucagon-like peptide 1 receptor agonists, mortality, and cardiovascular outcomes in serious mental illness. JAMA psychiatry.